Soluble epoxide hydrolase inhibitor

Soluble epoxide hydrolase inhibitor is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase (h-sEH) with pIC50 of 8.4, extracted from patent WO 2010096722 A1, example 57.

Signaling Pathways >> Others >> Others

Research Areas >> Cardiovascular Disease

Research Areas >> Metabolic Disease

pIC50: 8.4 (h-sEH)[1]

Soluble epoxide hydrolase inhibitor (Example 57) is an inhibitor of soluble epoxide hydrolase, and inhibits human soluble epoxide hydrolase with pIC50 of 8.4[1].

The sEH inhibitory properties of test compounds (including Soluble epoxide hydrolase inhibitor) are determined using a black 384-well-plate format under the following reaction conditions: 20 mM Tris pH 7.0, 0.1 mM EDTA, 0.1 mg/mL BSA, 5 μM PHOME (substrate), 2 nM sEH enzyme, 1% DMSO (from test compound). Reaction product is determined quantitatively by fluorescence intensity using a Fluorescence plate reader with an excitation wavelength at 330 nm and emission at 465 nm[1].

[1]. 3-OXO-2, 3-DIHYDRO- [1,2, 4] TRIAZOLO [4, 3-A]PYRIDINES AS SOLUBLE EPOXIDE HYDROLASE (SEH) INHIBITORS. WO 2010096722 A1

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline